

Editor's Note: In our May '09 issue we mistakenly printed the wrong indication for Velcade®. The correct indication for Velcade is listed in the table below.

IBs / MABs FDA-APPROVED

Generic Name	Brand Name	Company	Indication(s)	FDA Approval Year
alemtuzumab	Campath®	Genzyme/Berlex Laboratories	B-cell chronic CLL	May-01
bevacizumab	Avastin®	Genentech/Roche	CRC*; NSCLC**; metastatic HER2 positive BrC***	Feb 2004*; Oct 2006**; Feb 2008
bortezomib	Velcade®	Millennium	a proteasome inhibitor indicated for: <ul style="list-style-type: none"> • treatment of patients with multiple myeloma* • treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy** 	June 2008*; Dec 2006**
cetuximab	Erbix®	BMS/Merck/ImClone	EGFR-expressing CRC*; in combination with radiation for initial treatment of a certain type of locally or regionally advanced head and neck cancer**	Feb 2004*; Mar 2006**
dasatinib	Sprycel®	BMS	for chronic, accelerated, myeloid and lymphoid blast phases of CML including imatinib-resistance	Jun-06
erlotinib	Tarceva®	Genentech/OSI/Roche	advanced refractory metastatic NSCLC	Nov-04
gemtuzumab	Mylotarg®	Wyeth	CD33-positive AML	May-00
genfitinib	Iressa®	AstraZeneca	second-line treatment of NSCLC	May 2003; but in 2005 the revised label states that it is only to be given to pts who have benefitted prior to 2005
ibrutinomab	Zevalin®	Biogen IDEC	relapsed or refractory low-grade, follicular, or transformed B-cell NHL including pts with rituximab-refractory, follicular NHL	Feb-02
imatinib	Gleevec®	Novartis	Ph+ CML*; GIST*; second-line treatment for refractory CML**	May 2001*; Dec 2003**
lapatinib	Tykerb®	GSK	BrC	Mar-07
nilotinib	Tasigna®	Novartis	CML	Oct-07
panitumumab	Vectibex®	Amgen	CRC	Sep-06
pazopanib	Votrient™	GSK	Advanced RCC	Oct-09
rituximab	Rituxan®	Genentech/Roche	relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent*; for previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy**; for non-progressing (including stable disease), low-grade, CD20-positive B-cell NHL, as a single agent after first-line CVP chemotherapy**; for previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens**	Nov 1997*; Feb 2006**
sorafenib	Nexavar®	Bayer/Onyx	RCC	Dec-05
sunitinib	Sutent®	Pfizer	advanced RCC; GIST	Jan-06
tositumomab	Bexar®	GSK	for the treatment of CD20-positive, follicular NHL with and without transformation, whose disease is refractory to Rituxan and chemotherapy	Jun-03
trastuzumab	Herceptin®	Genentech/Roche/Chugai	HER2-positive MBC*; as part of a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel for the adjuvant treatment HER2-positive, node-positive, breast cancer**; as a single agent for the adjuvant treatment of HER2-positive, node-negative (ER/PR-negative or with one high-risk feature), or node-positive breast cancer, following multi-modality anthracycline-based therapy***; as a single agent and in early-stage HER2-positive node-negative disease, including tumors that are hormone receptor-negative, grade 2 or 3 or >2 cm, or age <35***; as a single agent in an every-three-week dosing schedule for one year***; in combination with docetaxel and carboplatin, as part of a treatment regimen containing anthracycline (doxorubicin), cyclophosphamide, and docetaxel (AC-TH)^	September 1998*; November 2006**; January 2008***, May 2008^

IBs / MABs IN DEVELOPMENT

Generic Name	Brand Name	Investigational Name	Company	Area of Study	Phase
adecatumumab		MT201	Merck/Micromet	BrC	I, II
alvocidib		HMR1275	Sanofi-Aventis	CLL	III
apomab			Genentech/Roche	NHL, NSCLC, CRC	I, II
axitinib		AG013736	Pfizer	BrC, CRC, melanoma, NSCLC, RCC, thyroid cancer, various cancer types	I-III
bavituximab			Peregrin Pharmaceuticals	BrC, NSCLC, various cancer types	I, II
blinatumomab		MT103/MEDI-538	Micromet	ALL, NHL	I, II
bosutinib		SKI-606	Wyeth	BrC, CML	II, III
brivanib			BMS	HCC, CRC	III
carfilzomib		PR-171	Proteolix	MM, lymphoma, various cancer types	I, II
cediranib	Recentin™		AstraZeneca	CRC, glioblastoma multiforme (GBM), NSCLC	II, III
dacetuzumab		SGN-40	Genentech/Roche/Seattle Genetics	MM, NHL, diffuse large B-cell lymphoma (DLBCL)	I, II
denosumab		AMG 162	Amgen	prevention of bone cancer-related bone loss and bone damage, MM	III
elotuzumab		Huluc63	BMS/Facet Biotech	MM	I
epratuzumab			Immunomedics	ALL, follicular-NHL, diffuse large B-cell lymphoma (DLBCL)	II
figitumumab		CP-751871	Pfizer	BrC, CRC, NSCLC, hormone insensitive prostate cancer (HRPC), Ewing's Sarcoma	I-III
galiximab			Biogen Idec	NHL	III
inotuzumab ozogamicin		CMC-544	Wyeth	NHL, f-NHL, DLBCL	II
ipilimumab		MDX-010	BMS/Medarex	melanoma, various cancer types	I-III
ispinesib		SB-715992	Cytokinetics	leukemia, pediatric solid tumor, BrC, various cancer types	I, II
labetuzumab			Immunomedics	CRC	II
lintuzumab		SGN-33	Seattle Genetics	AML, myelodysplastic syndrome (MDS)	I, II
lucatumumab		HCD122	Novartis	hematological malignancies	I
lumiliximab			Biogen Idec	CLL	II
mapatumumab		HGS-ETR1	Human Genome Sciences	MM, NSCLC	II
milatuzumab			Immunomedics	CLL, MM, NHL	I
motesanib diphosphate		AMG 706	Amgen	NSCLC, BrC	II, III
neratinib		HKI-272	Wyeth	BrC	II
nimotuzumab			YM Biosciences	CRC, esophageal cancer, gastric cancer, glioma, head and neck cancer, NSCLC, pancreatic cancer	II, III
ofatumumab	Arzerra™	HuMax-CD20	Genmab/GSK/Medarex	NHL, CLL, f-NHL, relapsed diffuse large B-cell lymphoma	II, III
pertuzumab	Omnitarg™		Genentech/Roche	BrC, ovarian cancer, NSCLC	II, III
robatumumab			Schering-Plough	various cancer types	II
sc veltuzumab			Immunomedics	CLL, NHL	I
seliciclib		CYC202	Cyclacel Pharmaceuticals	nasopharyngeal cancer, NSCLC	II
trastuzumab-DM1			Genentech/Immunogen/Roche	BrC	I-III
tremelimumab			Pfizer/Medarex	NSCLC, RCC, melanoma, various cancer types	II, III
vandetanib	Zactima™		AstraZeneca	NSCLC, medullary thyroid cancer (MTC)	II, III
volociximab		M200	Biogen Idec/Facet Biotech	NSCLC, ovarian cancer, various cancer types	II
Y-epratuzumab			Immunomedics	NHL	II
zalutumumab			Genmab/Medarex	head and neck cancer, cutaneous T-cell lymphoma (CTCL)	III